JP2009510165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510165A5 JP2009510165A5 JP2008534614A JP2008534614A JP2009510165A5 JP 2009510165 A5 JP2009510165 A5 JP 2009510165A5 JP 2008534614 A JP2008534614 A JP 2008534614A JP 2008534614 A JP2008534614 A JP 2008534614A JP 2009510165 A5 JP2009510165 A5 JP 2009510165A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cells
- composition according
- agent
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 42
- 210000004027 cells Anatomy 0.000 claims 17
- 206010021143 Hypoxia Diseases 0.000 claims 11
- 230000001146 hypoxic Effects 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 claims 8
- 210000001185 Bone Marrow Anatomy 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 229940079593 drugs Drugs 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000000601 Blood Cells Anatomy 0.000 claims 2
- 241000219198 Brassica Species 0.000 claims 2
- 235000003351 Brassica cretica Nutrition 0.000 claims 2
- 235000003343 Brassica rupestris Nutrition 0.000 claims 2
- 102100003042 HIF1A Human genes 0.000 claims 2
- 101700000053 HIF1A Proteins 0.000 claims 2
- QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical group C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 claims 2
- 229950002376 Tirapazamine Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000000779 depleting Effects 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 235000010460 mustard Nutrition 0.000 claims 2
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 claims 1
- KIMCGLHTSSZPNS-UHFFFAOYSA-N 2,3-dinitrobenzamide Chemical compound NC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O KIMCGLHTSSZPNS-UHFFFAOYSA-N 0.000 claims 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 claims 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N AZOMYCIN Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 1
- RZVHIXYEVGDQDX-UHFFFAOYSA-N Anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 210000004700 Fetal Blood Anatomy 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- IGGVVGHJSQSLFO-UHFFFAOYSA-N Indole-5,6-quinone Chemical compound O=C1C(=O)C=C2C=CNC2=C1 IGGVVGHJSQSLFO-UHFFFAOYSA-N 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- OQQVFCKUDYMWGV-UHFFFAOYSA-N [5-(1-benzylindazol-3-yl)furan-2-yl]methanol Chemical compound O1C(CO)=CC=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1 OQQVFCKUDYMWGV-UHFFFAOYSA-N 0.000 claims 1
- OZNRZINTTRZGCV-UHFFFAOYSA-M amino-[nitro(phenyl)methoxy]phosphinate Chemical compound NP([O-])(=O)OC([N+]([O-])=O)C1=CC=CC=C1 OZNRZINTTRZGCV-UHFFFAOYSA-M 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- JAWGVVJVYSANRY-UHFFFAOYSA-N cobalt(3+) Chemical group [Co+3] JAWGVVJVYSANRY-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 230000002519 immonomodulatory Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulators Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229950010514 misonidazole Drugs 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 239000003638 reducing agent Substances 0.000 claims 1
- 101710004466 rgy Proteins 0.000 claims 1
- 101710030364 rgy1 Proteins 0.000 claims 1
- 101710030359 rgy2 Proteins 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- OBBCSXFCDPPXOL-UHFFFAOYSA-N α-(methoxymethyl)-2-nitro-1H-Imidazole-1-ethanol Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72318305P | 2005-10-03 | 2005-10-03 | |
| PCT/US2006/038553 WO2007041546A2 (en) | 2005-10-03 | 2006-09-29 | Method for selectively depleting hypoxic cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009510165A JP2009510165A (ja) | 2009-03-12 |
| JP2009510165A5 true JP2009510165A5 (pt-PT) | 2009-11-05 |
Family
ID=37826084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534614A Pending JP2009510165A (ja) | 2005-10-03 | 2006-09-29 | 低酸素細胞を選択的に枯渇させるための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090136521A1 (pt-PT) |
| EP (1) | EP1931769A2 (pt-PT) |
| JP (1) | JP2009510165A (pt-PT) |
| CA (1) | CA2624707A1 (pt-PT) |
| WO (1) | WO2007041546A2 (pt-PT) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2414475C2 (ru) | 2005-06-29 | 2011-03-20 | Трешолд Фармасьютикалз, Инк. | Пролекарства фосфорамидатных алкилаторов |
| NZ549831A (en) * | 2006-09-11 | 2009-03-31 | Auckland Uniservices Ltd | Combination of docetaxel and a nitrophenyl phosphate derivative for the treatment of cancer |
| WO2008033039A1 (en) * | 2006-09-11 | 2008-03-20 | Adam Vorn Patterson | Cancer treatment |
| WO2009067489A1 (en) * | 2007-11-20 | 2009-05-28 | Lankenau Institute For Medical Research | Disulfide chemotherapeutic agents and methods of use thereof |
| CN101683319B (zh) * | 2008-09-24 | 2012-09-05 | 杭州民生药业有限公司 | 一种替拉扎明非肠道给药含水制剂及其制备方法 |
| JP5765634B2 (ja) | 2008-10-21 | 2015-08-19 | スレッシュホールド ファーマシューティカルズ， インコーポレイテッド | 低酸素活性化型プロドラッグを用いるがんの処置 |
| WO2010132771A1 (en) | 2009-05-15 | 2010-11-18 | Lankenau Institute For Medical Research | Methods and kits for measuring toxicity and oxidative stress in live cells |
| US8269197B2 (en) | 2009-07-22 | 2012-09-18 | Intraop Medical Corporation | Method and system for electron beam applications |
| EP2542307A4 (en) * | 2010-03-01 | 2013-10-09 | Intraop Medical Corp | COMBINED RADIOTHERAPY WITH HYPOXIC CELL SENSITILIZERS |
| EP3311835B1 (en) | 2010-07-12 | 2021-03-24 | Threshold Pharmaceuticals Inc. | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| US9254299B2 (en) | 2011-12-22 | 2016-02-09 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer |
| US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| JP2016528217A (ja) | 2013-07-26 | 2016-09-15 | スレッショルド ファーマシューティカルズ，インコーポレイテッド | 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 |
| US9808011B2 (en) | 2014-12-15 | 2017-11-07 | Biovectra Inc. | Pentacyclic triterpene compounds and uses thereof |
| EP3313385B8 (en) | 2015-06-24 | 2021-04-21 | ImmunoGenesis, Inc. | Aziridine containing dna alkylating agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794742A (fr) * | 1972-02-01 | 1973-07-30 | Bayer Ag | Nouveaux di-n-oxydes (1,4) de benzo-1,2,4-triazine, leur procede de preparation et leur application comme medicaments et additifs de nutrition |
| US3957779A (en) * | 1972-11-15 | 1976-05-18 | Bayer Aktiengesellschaft | Benzo-1,2,4-triazines |
| US5175287A (en) * | 1986-09-25 | 1992-12-29 | S R I International | Process for preparing 1,2,4-benzotriazine oxides |
| US5484612A (en) * | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| US5672702A (en) * | 1995-12-04 | 1997-09-30 | Sanofi | Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide |
| EP1014990B1 (en) * | 1997-03-07 | 2006-09-06 | Sanofi-Aventis U.S. LLC | Antitumor combination of 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum |
| WO1999045126A2 (en) * | 1998-03-06 | 1999-09-10 | Oxford Biomedica (Uk) Limited | Enhanced prodrug activation |
-
2006
- 2006-09-29 US US11/992,898 patent/US20090136521A1/en not_active Abandoned
- 2006-09-29 CA CA002624707A patent/CA2624707A1/en not_active Abandoned
- 2006-09-29 JP JP2008534614A patent/JP2009510165A/ja active Pending
- 2006-09-29 WO PCT/US2006/038553 patent/WO2007041546A2/en active Application Filing
- 2006-09-29 EP EP06816085A patent/EP1931769A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009510165A5 (pt-PT) | ||
| US11433137B2 (en) | Compounds for treating cancer | |
| US10179787B2 (en) | Chemokine receptor modulators and uses thereof | |
| US11384064B2 (en) | Chemokine receptor modulators and uses thereof | |
| US10166246B2 (en) | TGR5 agonist complexes for treating diabetes and cancer | |
| US10246462B2 (en) | Chemokine receptor modulators and uses thereof | |
| Zhang et al. | Targeting role of glioma stem cells for gliobastoma multiforme | |
| JP2019534308A5 (pt-PT) | ||
| JP2015534946A5 (pt-PT) | ||
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| JP2008535785A5 (pt-PT) | ||
| JP2012067116A5 (pt-PT) | ||
| JP2019515908A5 (pt-PT) | ||
| US10842763B2 (en) | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | |
| Huang et al. | Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced‐killer cells in a murine lung carcinoma model | |
| WO2020181802A1 (zh) | 一种有效抗恶性肿瘤的药物组合物及其应用 | |
| CN111789868A (zh) | 青蒿素类化合物在促进嵌合抗原受体t细胞治疗中的应用及药物组合物 | |
| JP2016502527A5 (pt-PT) | ||
| WO2017177515A1 (zh) | 4-羟基水杨酰苯胺在制备抗骨髓瘤、淋巴瘤药物中的应用 | |
| CN103417977A (zh) | 叶酸受体α亚型高效介导的靶向投药系统 | |
| Shi et al. | An overview of heavy chain ferritin in cancer | |
| JP2009538935A5 (pt-PT) | ||
| WO2021143754A1 (zh) | 用于癌症治疗的组合及其应用 | |
| Alshaker et al. | PO-432 New combined nanoparticle therapy inhibits metastatic breast tumour growth with superior efficacy and lower side effect profile to docetaxel | |
| Gutkin et al. | DDIS-03. HARNESSING siRNA NANOMEDICINE FOR THERAPEUTIC GENE SILENCING IN GLIOBLASTOMA |